Enanta Pharmaceuticals | ENTA - Current Assets


Enanta Pharmaceuticals reported $198.68M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Amgen USD 31.48B 2.42B Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Biogen USD 9.19B 216.3M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Immunic USD 22.87M 16.4M Dec/2025
Incyte USD 5.48B 460.36M Mar/2026
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026